GLP-1 (7-37) acetate | Insulinotropin | CAS#106612-94-6 | insulin stimulator

MedKoo Cat#: 326644 | Name: Insulinotropin acetate [GLP-1 (7-37)]

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Insulinotropin, also known as GLP-1 (7-37) and Tglp-1, is a potent stimulator of insulin secretion at concentrations as low as 5 X 10(-11) M (3- to 10-fold increases over basal). GLP-I(1-37) had no effect on insulin secretion even at concentrations as high as 5 X 10(-7) M. The earlier demonstration of specific liberation of GLP-I(7-37) in the intestine and pancreas, and the magnitude of the insulinotropic effect at such low concentrations, suggest that GLP-I(7-37) participates in the physiological regulation of insulin secretion.

Chemical Structure

Insulinotropin acetate [GLP-1 (7-37)]

CAS#106612-94-6 (free base).

Theoretical Analysis

MedKoo Cat#: 326644

Name: Insulinotropin acetate [GLP-1 (7-37)]

CAS#: 106612-94-6 (free base).

Chemical Formula: C159H244N40O55

Exact Mass:

Molecular Weight: 3595.93

Elemental Analysis: C, 53.11; H, 6.84; N, 15.58; O, 24.47

Price and Availability

Size	Price	Availability	Quantity
1g	USD 4,950.00
2g	USD 8,950.00
5g	USD 15,650.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

GLP-1 (7-37) peptide; Glucagon like Peptide-1 (7-37) Acetate. Insulinotropin. Tglp-1.

IUPAC/Chemical Name

His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly, tetracetate

InChi Key

BTRLPDHSLYZFFN-JJCNJTQWSA-N

InChi Code

InChI=1S/C151H228N40O47.4C2H4O2/c1-17-77(10)121(148(236)169-81(14)127(215)177-105(60-87-63-160-92-36-25-24-35-90(87)92)138(226)179-101(56-74(4)5)139(227)188-119(75(6)7)146(234)176-94(37-26-28-52-152)130(218)161-65-111(199)170-93(39-30-54-159-151(156)157)129(217)164-68-118(210)211)190-140(228)103(57-84-31-20-18-21-32-84)180-135(223)99(47-51-116(206)207)175-134(222)95(38-27-29-53-153)172-125(213)79(12)166-124(212)78(11)168-133(221)98(44-48-110(155)198)171-112(200)66-162-132(220)97(46-50-115(204)205)174-136(224)100(55-73(2)3)178-137(225)102(59-86-40-42-89(197)43-41-86)181-143(231)107(69-192)184-145(233)109(71-194)185-147(235)120(76(8)9)189-142(230)106(62-117(208)209)182-144(232)108(70-193)186-150(238)123(83(16)196)191-141(229)104(58-85-33-22-19-23-34-85)183-149(237)122(82(15)195)187-113(201)67-163-131(219)96(45-49-114(202)203)173-126(214)80(13)167-128(216)91(154)61-88-64-158-72-165-88;4*1-2(3)4/h18-25,31-36,40-43,63-64,72-83,91,93-109,119-123,160,192-197H,17,26-30,37-39,44-62,65-71,152-154H2,1-16H3,(H2,155,198)(H,158,165)(H,161,218)(H,162,220)(H,163,219)(H,164,217)(H,166,212)(H,167,216)(H,168,221)(H,169,236)(H,170,199)(H,171,200)(H,172,213)(H,173,214)(H,174,224)(H,175,222)(H,176,234)(H,177,215)(H,178,225)(H,179,226)(H,180,223)(H,181,231)(H,182,232)(H,183,237)(H,184,233)(H,185,235)(H,186,238)(H,187,201)(H,188,227)(H,189,230)(H,190,228)(H,191,229)(H,202,203)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,156,157,159);4*1H3,(H,3,4)/t77-,78-,79-,80-,81-,82+,83+,91-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,119-,120-,121-,122-,123-;;;;/m0..../s1

SMILES Code

O=C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C(C)C)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCCN)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCNC(N)=N)C(NCC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC6=CNC=N6)N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

In vitro activity:

Compared with the control valves, the concentration of GLP-1 decreased in the calcific aortic valves by 39% (CAVD: 5,606 ± 750.4; vs. Control valves: 9,170 ± 695.9; P = 0.0042) (Figures 2A,B). A reduction in GLP-1 was associated with CAVD (calcific aortic valve disease), and GLP-1 participated in the mineralization of AVICs by regulating specific calcific genes. GLP-1 warrants consideration as a novel treatment target for CAVD. Reference: Front Cardiovasc Med. 2021 Aug 26;8:709741. https://pubmed.ncbi.nlm.nih.gov/34513952/

In vivo activity:

This study studied the effects of synthetic GLP-Is on insulin secretion in the isolated perfused rat pancreas. In the presence of 6.6 mM glucose, GLP-I(7-37) is a potent stimulator of insulin secretion at concentrations as low as 5 X 10(-11) M (3- to 10-fold increases over basal). Reference: J Clin Invest. 1987 Feb;79(2):616-9. https://pubmed.ncbi.nlm.nih.gov/3543057/

	Solvent	mg/mL	mM
Solubility
	Water	30.0	8.34

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 3,595.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Xiao F, Zha Q, Zhang Q, Wu Q, Chen Z, Yang Y, Yang K, Liu Y. Decreased Glucagon-Like Peptide-1 Is Associated With Calcific Aortic Valve Disease: GLP-1 Suppresses the Calcification of Aortic Valve Interstitial Cells. Front Cardiovasc Med. 2021 Aug 26;8:709741. doi: 10.3389/fcvm.2021.709741. PMID: 34513952; PMCID: PMC8428521. 2. Hoffman S, Alvares D, Adeli K. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Mol Metab. 2022 Nov;65:101590. doi: 10.1016/j.molmet.2022.101590. Epub 2022 Sep 5. PMID: 36067913; PMCID: PMC9486018. 3. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987 Feb;79(2):616-9. doi: 10.1172/JCI112855. PMID: 3543057; PMCID: PMC424143.

In vitro protocol:

In vivo protocol:

1. Hoffman S, Alvares D, Adeli K. GLP-1 attenuates intestinal fat absorption and chylomicron production via vagal afferent nerves originating in the portal vein. Mol Metab. 2022 Nov;65:101590. doi: 10.1016/j.molmet.2022.101590. Epub 2022 Sep 5. PMID: 36067913; PMCID: PMC9486018. 2. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987 Feb;79(2):616-9. doi: 10.1172/JCI112855. PMID: 3543057; PMCID: PMC424143.

1: Nakata M, Shintani N, Hashimoto H, Baba A, Yada T. Intra-islet PACAP protects pancreatic β-cells against glucotoxicity and lipotoxicity. J Mol Neurosci. 2010 Nov;42(3):404-10. doi: 10.1007/s12031-010-9383-4. Epub 2010 May 12. PubMed PMID: 20461496. 2: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PubMed PMID: 18200333. 3: Andoh T. Amino acids are more important insulinotropins than glucose in a teleost fish, barfin flounder (Verasper moseri). Gen Comp Endocrinol. 2007 May 1;151(3):308-17. Epub 2007 Jan 25. PubMed PMID: 17350013. 4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Oct;26(8):639-63. PubMed PMID: 15605126. 5: Yanagida K, Yaekura K, Arima T, Yada T. Glucose-insensitivity induced by Ca(2+) toxicity in islet beta-cells and its prevention by PACAP. Peptides. 2002 Jan;23(1):135-42. PubMed PMID: 11814628. 6: Yada T, Nakata M, Shioda S. Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes. Ann N Y Acad Sci. 2000;921:473-7. PubMed PMID: 11193879. 7: Nakata M, Shioda S, Oka Y, Maruyama I, Yada T. Insulinotropin PACAP potentiates insulin-stimulated glucose uptake in 3T3 L1 cells. Peptides. 1999;20(8):943-8. PubMed PMID: 10503772. 8: Plisetskaya EM, Mommsen TP. Glucagon and glucagon-like peptides in fishes. Int Rev Cytol. 1996;168:187-257. Review. PubMed PMID: 8843650. 9: Kim Y, Haren AM. The application of crystal soaking technique to study the effect of zinc and cresol on insulinotropin crystals grown from a saline solution. Pharm Res. 1995 Nov;12(11):1664-70. PubMed PMID: 8592667. 10: Qi H, Heller DL. Stability and stabilization of insulinotropin in a dextran formulation. PDA J Pharm Sci Technol. 1995 Nov-Dec;49(6):289-93. PubMed PMID: 8581460. 11: Kim Y, Rose CA. Precipitation of insulinotropin in the presence of protamine: effect of phenol and zinc on the isophane ratio and the insulinotropin concentration in the supernatant. Pharm Res. 1995 Sep;12(9):1284-8. PubMed PMID: 8570522. 12: Kim Y, Rose CA, Liu Y, Ozaki Y, Datta G, Tu AT. FT-IR and near-infrared FT-Raman studies of the secondary structure of insulinotropin in the solid state: alpha-helix to beta-sheet conversion induced by phenol and/or by high shear force. J Pharm Sci. 1994 Aug;83(8):1175-80. PubMed PMID: 7983604. 13: Brophy RT, Lambert WJ. The adsorption of insulinotropin to polymeric sterilizing filters. J Pharm Sci Technol. 1994 Mar-Apr;48(2):92-4. PubMed PMID: 8032801. 14: Koyama N, Kuriyama M, Amano N, Nishimura O. A novel procedure for the preparation of biologically active recombinant peptides using a cyanylation reaction. J Biotechnol. 1994 Feb 28;32(3):273-81. PubMed PMID: 7764719. 15: Mommsen TP, Plisetskaya EM. Metabolic and endocrine functions of glucagon-like peptides - evolutionary and biochemical perspectives. Fish Physiol Biochem. 1993 Jul;11(1-6):429-38. doi: 10.1007/BF00004593. PubMed PMID: 24202503. 16: Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993 Jun 15;214(3):829-35. PubMed PMID: 8100523. 17: Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987 Feb;79(2):616-9. PubMed PMID: 3543057; PubMed Central PMCID: PMC424143.